"Agentic AI builds on the recent advancements in LLMs' reasoning capabilities but couples them with external tools, memory, and data sources, enabling systems that can 'think', 'act', 'observe', and 'reflect' in iterative loops."
— Seal et al., AI Agents in Drug Discovery (2026)3
Commentary|Articles|September 10, 2026
The Agentic AI Revolution in Biopharma
Author(s)Partha Anbil, Satish Tadikonda
Listen
0:00 / 0:00
How agentic artificial intelligence is transforming the value chain from discovery to commercialization.
Advertisement
Executive Summary
The biopharmaceutical industry is undergoing a profound transformation, driven by the emergence of agentic artificial intelligence (AI). Unlike traditional AI models that require continuous human guidance, agentic AI systems function as autonomous partners that can reason, learn, and execute complex tasks with minimal intervention.
These intelligent agents are not merely tools but are becoming integral coworkers, poised to reimagine workflows, accelerate innovation, and unlock unprecedented efficiency across the entire biopharma value chain. From the initial stages of drug discovery to commercialization and post-market surveillance, agentic AI is catalyzing a paradigm shift that promises to deliver life-saving therapies to patients faster and more cost-effectively than ever before.
This report provides a comprehensive overview of the expanding role of agentic AI in the biopharma industry. It explores the broad, cross-functional impact of this technology and delves into specific applications and real-world case studies across key stages of the value chain: discovery, clinical development, regulatory affairs, commercial operations, manufacturing, and pharmacovigilance.
The analysis synthesizes findings from recent industry reports, academic research, and expert commentary to illustrate how agentic AI is not just an incremental improvement but a fundamental force reshaping the future of medicine.
1. The Broad Impact: A Paradigm Shift in Operations and Productivity
The adoption of agentic AI is projected to have a sweeping impact on the biopharma industry's operational landscape and financial performance. A comprehensive analysis by McKinsey & Company found that 75% to 85% of all workflows in the pharmaceutical sector contain tasks that can be automated or significantly augmented by AI agents.
This widespread integration is expected to free up 25% to 40% of organizational capacity, allowing highly skilled professionals to shift their focus from routine, manual tasks to more strategic, high-value activities, such as innovation, complex problem-solving, and scientific exploration.1The financial implications are equally significant.
McKinsey projects that agentic AI could drive an incremental revenue growth of 5 to 13 percentage points and boost EBITDA by 3.4 to 5.4 percentage points for pharmaceutical companies within the next three to five years. This transformation is not limited to a few niche areas.
Up to 95% of roles within a life sciences organization are expected to interact with agentic AI systems as teammates, fundamentally altering the nature of work and collaboration. Gartner predicts that by 2027, half of all business decisions will be augmented or automated by AI agents for decision intelligence.1
This shift moves AI from a passive tool to an active collaborator. Instead of simply executing predefined commands, AI agents can now independently manage complex workflows, synthesize vast datasets, generate hypotheses, and even orchestrate physical experiments in a closed loop.
The greatest productivity boost may come from agents performing tasks that humans are not currently doing. McKinsey found that 40% of workflows include tasks that are too complex or uneconomical for humans to perform, but that agents could manage at scale.1
2. Use Cases Across the Biopharma Value Chain
The following sections explore how agentic AI is being applied across each major stage of the biopharma value chain, from early-stage discovery through to post-market surveillance. Each section provides an overview of the transformation underway and highlights specific, real-world examples and case studies.2
2.1 Discovery and Research & Development
The earliest stages of the drug development pipeline—traditionally characterized by prohibitive costs, long timelines, and a high failure rate—are being revolutionized by agentic AI. These systems are accelerating discovery by automating and optimizing nearly every aspect of R&D.
With agentic AI, early-stage drug discovery and scientific exploration can be reimagined through autonomous data analysis, data-driven drug-candidate selection, and accelerated regulatory submission preparation.3,4
A seminal 2026 paper, "AI Agents in Drug Discovery," details several operational agentic systems that are already demonstrating remarkable results. These systems employ various architectures—from simple ReAct (Reasoning-Acting) loops to complex multi-agent supervisors and swarm systems—to tackle diverse challenges in the discovery pipeline.3
Key Examples in Discovery
- Kiin Bio's "Virtual Scientists" Platform: This multi-agent system orchestrated an end-to-end drug discovery program for Idiopathic Pulmonary Fibrosis (IPF), completing a process that typically takes two to three weeks in under two hours. The platform integrated specialized agents for literature reviews, omics data analysis, structural biology modeling, and generative chemistry to identify novel targets and rank potential small molecule hits. The system captures experimental context at every stage, enabling more accurate prioritization and reducing redundancy.3
- Automated Protocol Design (Tater Agent): Developed by Happy Potato, the "Tater" agent compressed qPCR assay design and validation from a 1–4-month manual process to under two hours—a greater than 400-fold reduction in cycle time. The agent autonomously reviewed literature, compared methods, generated a MIQE-aligned protocol, and produced executable code for a liquid-handling robot (Opentrons), all while maintaining full traceability and auditability.3
- In Silico Toxicity Prediction (Human Chemical): Deployed a ReAct-based agentic system to conduct comprehensive toxicological assessments. In a case study on the fragrance compound Cashmeran, the system predicted endocrine disruption hazards, automatically ran predictions on its metabolites, conducted a full literature review, and synthesized findings into a risk assessment report, demonstrating how AI agents can augment human expertise in chemical safety assessment.3
- Drug Repurposing for Rare Diseases (Augmented Nature): A supervisor-agent architecture accelerated drug repurposing for spinal muscular atrophy (SMA). A team of specialized agents—including disease, pathway, protein, compound, and safety agents—autonomously searched across genomic, pathway, structural, and chemical databases to generate a shortlist of repurposable ligands in hours, a task that would manually take weeks.3
- Automated Small Molecule Synthesis (onepot.ai): An agentic platform integrated with laboratory hardware is automating the physical synthesis of small molecules. The system includes a retrosynthesis engine and tools for web search and literature analysis and can execute organic chemistry experiments with success rates of 50–88%, synthesizing tens of compounds per day and dramatically shortening the design-make-test-analyze (DMTA) cycle.3
2.2 Clinical Development
Clinical development, which accounts for nearly 70% of total R&D expenses, is another area ripe for transformation. Agentic AI streamlines complex trial processes, leading to significant gains in speed, efficiency, and quality.
McKinsey estimates that agentic AI can boost productivity in clinical development by 35% to 45%, with benefits accruing to every function involved in bringing a drug from the laboratory to the patient.5
Trial Design and Start-Up
AI agents are optimizing trial design by benchmarking against similar trials, evaluating competitive landscapes, and simulating outcomes using machine learning. A clinical trial agent identifies similar trials and establishes key metrics, while a literature explorer agent evaluates unmet needs.
A trial optimizer agent then refines the design, and a document-generation agent produces a draft protocol in minutes. This approach can enable companies to design trials 50% faster with 25% fewer amendments.
During study start-up, agents automate site selection based on performance data and demographics, draft "first time-right" contracts based on reasonable value, and coordinate site outreach, which can double site activation rates with 30%–50% fewer staff.5
Data Management and Statistical Programming
The traditional linear and manual process of clinical data management is becoming dynamic and iterative. Agentic platforms combine large language models with domain-specific heuristics to automatically identify, prioritize, and resolve data discrepancies, resulting in two to three times fewer queries.
This boosts data management productivity by 60% and reduces database build timelines from two to three months to under two weeks. Statistical programming is similarly transformed, with agents automating derivation code generation and enabling parallel processing of datasets.5
Document Generation
Agentic AI is dramatically accelerating the authoring of crucial documents, such as clinical study reports (CSRs). A multi-agent architecture developed by McKinsey in partnership with a large pharmaceutical client cut CSR drafting errors by 50% and reduced the time from database lock to report finalization from ~12 weeks to 6.
These systems autonomously plan data extraction, perform analyses, and generate high-quality drafts with full traceability. This capability is being expanded to protocols, informed consent forms, and other crucial documents.5
Trial Management Copilots
Leading pharmaceutical companies are deploying multi-agent trial copilots to provide real-time oversight of clinical operations. These systems monitor site activation, patient enrollment, and data management, analyzing data from clinical control towers to identify underperforming sites and suggest remedial actions.
One major company plans to upgrade its agents to enable direct interaction with principal investigators and clinical research associates for routine tasks, further reducing operational workload.5
2.3 Regulatory Affairs
Navigating the complex and stringent landscape of global regulatory affairs is a crucial function in which agentic AI is beginning to make a significant impact. The overarching goal is to improve submission quality, shorten review cycles, and increase the likelihood of first-cycle approvals from agencies such as FDA and the European Medicines Agency (EMA).5,6
Automated Regulatory Document Generation
Agentic AI excels at compiling and authoring complex regulatory documents. Systems can autonomously gather the latest efficacy, safety, and manufacturing data to produce high-quality, compliant drafts of submission dossiers, clinical study reports, and safety reports.
McKinsey notes that documentation agents can achieve 75%–80% productivity gains for initial document generation, with additional benefits from collaboration with review agents that ensure compliance with regulatory and quality standards. End-to-end document generation and review agents can cut turnaround times from weeks to hours.5
The "Virtual Regulator" Concept
A groundbreaking concept being developed is the creation of a “virtual regulator”—a digital twin of global health authorities. This agentic system, powered by a proprietary knowledge base of past submissions and regulatory feedback, can simulate a regulator's review process.
It performs real-time content reviews based on past feedback, regulatory examples, and guideline sets (including ICH E3 and E6), proactively flagging ambiguous language, unsupported claims, and structural issues before the submission is sent. By simulating the perspectives of reviewers from the FDA, EMA, and other bodies, this approach is expected to reduce rework cycles, speed agency interactions, and increase first-cycle approval rates.
Overall, this is projected to reduce review time by up to 40 days.5,7,8
Intelligent Submission Management
A digital twin of a regulatory project manager can actively manage submission readiness, forecast resource needs, and reallocate subject matter experts as priorities change. When integrated with a document-review agent, this system can organize reviewer feedback by theme, highlighting high-priority and cross-functional issues for human consensus.
When a change is made in one document, the agent can automatically flag all related documents that need updating, maintaining alignment across the entire submission package and reducing the risk of errors.5
2.4 Commercial Operations
Beyond the lab and the clinic, agentic AI is also transforming the commercial side of the biopharma industry, from sales and marketing to market access and payer engagement. Commercial organizations in both pharma and medtech are grappling with rising engagement complexity, increasing demands for personalization from healthcare professionals (HCPs) and patients, and cost constraints.
McKinsey projects that agentic AI can drive a 4%–8% increase in revenue and a 5%–9% reduction in commercial spending during the next five years.1
Sales Engagement
Intelligent assistants are redefining how sales representatives engage with healthcare professionals. These agents support pre- and post-call activities, including HCP and territory planning, capturing insights from interactions, automating follow-up tasks, and providing personalized coaching feedback.
By synthesizing clinical evidence, product information, and engagement data, they enable more targeted and effective interactions. Virtual sales platforms can extend reach to hard-to-access territories and HCPs in a compliant, scalable way.
These innovations can reduce the burden on sales representatives by 15%–25% and increase revenue by up to 3% through improved targeting and stronger relationships. Companies such as Salesforce (with Agentforce) and ZS, in partnership with firms such as Pfizer and AstraZeneca, are actively developing CRM-integrated agentic AI solutions for this purpose.1,9,10
Marketing
Agentic AI is revolutionizing marketing workflows across strategic planning, content creation, review, campaign development and execution, and performance tracking. Self-serve platforms let marketers produce content independently, reducing reliance on external agencies and speeding up turnaround times.
Automated pre-MLR (medical, legal, and regulatory) review systems identify common issues before formal review, decreasing cycle times and improving compliance. Unified platforms that aggregate internal and external data, with conversational interfaces, help marketers understand brand performance and patient and HCP needs in real time.1,11
Market Access and Payer Engagement
In the complex world of market access, agentic AI is helping to optimize pricing and contracting strategies. Advanced gross-to-net optimization agents can simulate complex access scenarios at brand and portfolio levels, helping to inform trade-offs that were once difficult to make.
A contracting-intelligence platform can enable smarter contract decisions by analyzing past deals, modeling potential outcomes, and guiding negotiation strategies. Several manual tasks can also be automated, including creating initial contract drafts, monitoring performance, and tracking compliance.
Automated invoice auditing ensures contract terms are upheld and identifies discrepancies early, minimizing value leakage.1
2.5 Manufacturing and Supply Chain
Agentic AI is being deployed to enhance the efficiency, quality, and resilience of biopharma manufacturing and supply chains. Life sciences operations face many challenges, including high interdependence between subfunctions and the need for time-critical decision-making and extensive quality and compliance documentation.
McKinsey estimates that agent-based AI could help with 75%–85% of workflows in operations, reducing the time required for key tasks in supply chain, procurement, manufacturing, and quality by 25%–35%.1,2,12
Smart Manufacturing
In plant operations, agents can connect directly to manufacturing execution and process-information systems to detect and respond to deviations in real time. For example, they can increase yield and product quality by adjusting bioreactor parameters such as pH and oxygen levels, or by modifying machine settings, such as pressure, temperature, and linear motor speed for fully automated manufacturing lines.
This real-time responsiveness minimizes waste and ensures consistent product quality.1,12
Supply Chain Resilience and Planning
Orchestrating agents can enable multifunctional interactions across supply planning, raw material supply, and manufacturing, eliminating delays from inefficient communication and approval processes. Agents continuously monitor coordination, inventory levels, and production schedules, autonomously adjusting orders, rerouting shipments, and triggering interventions to prevent disruptions.
Procurement category management agents can track changes in raw material supply and commodity prices to initiate targeted negotiations, while supplier management agents observe performance metrics and detect negative trends before they significantly affect operations.1,12
Automated GMP Documentation
Operations teams spend considerable time manually drafting Good Manufacturing Practice (GMP) documents. Documentation agents can create templates for standardized documents by using historical reports and good documentation practices requirements to draft initial versions of standard operating procedures (SOPs), deviation reports, validation protocols, change control impact assessments, and technology transfer documents.1,5
2.6 Pharmacovigilance and Post-Market Surveillance
After a drug reaches the market, work to ensure safety and effectiveness continues. Agentic AI is enhancing pharmacovigilance and post-market surveillance by automating the monitoring, detection, and reporting of adverse events, enabling a more proactive approach to patient safety.2,11,13,14
AI agents can continuously monitor diverse data streams—including social media, electronic health records, patient-reported outcomes, and scientific literature—to identify potential safety signals in real time. A notable example is Novartis's "AE Brain," an AI-powered system designed for efficient social media monitoring in pharmacovigilance.
Such systems can process vast volumes of unstructured data far more quickly and comprehensively than manual review, flagging potential adverse events for human expert assessment.11,13-15 Beyond signal detection, agentic AI is also being applied to AI-enabled patient support programs.
These programs leverage intelligent agents to monitor patient adherence, predict potential health crises, and customize treatment schedules. By integrating data from wearable sensors, mobile apps, and electronic health records, these agents can provide a more holistic and responsive approach to post-market patient care, ultimately improving outcomes and strengthening the safety profile of marketed products.11,13,14
3. Challenges and Considerations
Although the potential of agentic AI in biopharma is immense, its successful adoption is not without significant challenges. Organizations must navigate a complex landscape of technical, regulatory, and organizational hurdles to realize the full benefits of this technology.
- Data Quality and Governance: Agentic AI systems are only as good as the data they consume. The pharmaceutical industry often struggles with fragmented data architectures, inconsistent master data, and siloed governance practices. Ensuring data are accurate, traceable, and fit for use across distinct functions and areas is a foundational prerequisite for effective AI deployment. Robust data governance frameworks, including compliance with GDPR, 21 CFR Part 11, and ICH guidelines, are essential.6-8
- System Reliability and Hallucination: AI agents, particularly those built on large language models, can produce outputs that are plausible but incorrect ("hallucinations"). In a highly regulated industry in which errors can directly affect patient safety, ensuring the reliability and accuracy of agentic output is paramount. Human-in-the-loop oversight remains crucial, especially for consequential decisions.3,6
- Regulatory and Ethical Compliance: The regulatory landscape for AI in pharma is still evolving. Companies must establish strong governance frameworks to ensure ethical use, including clear accountability for agent decisions, guardrails to prevent unintended consequences, regular audits, and bias-detection mechanisms. Transparency and explainability of AI-driven decisions are increasingly important to regulators and stakeholders.6,7
- Organizational Change Management: Implementing agentic AI is not just a technology challenge; it requires a fundamental rethinking of workflows, roles, and organizational structures. Leadership commitment, clear communication, and investment in reskilling the workforce are essential for successful adoption. New roles such as agent orchestrators, AI governance managers, and agent supervisors are expected to be created.1
- Infrastructure and Scalability: Moving from isolated pilots to enterprise-scale deployment requires significant investment in flexible, interconnected AI architectures. An enterprise-level agentic "foundry"—a centralized hub for continuously designing, training, and operating agents at scale—is needed to orchestrate the 30+ specialized agents required for full-scale development operations.5
5. Conclusion
Agentic AI represents a pivotal technological shift for the biopharma industry. It is not a distant future vision but a present-day reality, with tangible applications and measurable impact already being demonstrated across the value chain.
From accelerating the discovery of novel drug candidates by orders of magnitude to optimizing clinical trials, streamlining regulatory submissions, enhancing commercial effectiveness, and strengthening manufacturing operations, intelligent agents are functioning as transformative partners.1,3,5 By automating complex tasks, synthesizing vast amounts of data, and enabling more intelligent decision-making, agentic AI is freeing human experts to focus on what they do best: innovate, exercise scientific judgment, and build meaningful relationships.
The journey to full-scale adoption is expected to require strategic investment, reimagined workflows, robust data governance, and a focus on strong ethical and regulatory guardrails.1,6 However, the companies that successfully harness the power of this agentic workforce are poised to lead the next wave of medical breakthroughs.
They are expected to operate radically differently and more competitively, delivering more effective therapies to patients with unprecedented speed and precision. The question for biopharma leaders is no longer whether to adopt agentic AI, but how quickly and how strategically they can integrate it into the fabric of their organizations.
Disclaimer: The views expressed in the article are those of the authors and not of the organizations they represent.
About the Authors
Partha Anbil is at the intersection of the Life Sciences industry and Management Consulting. He has more than 30 years of experience in Life Sciences. He is also a Life Sciences industry advisor at MIT, his alma mater. He held senior leadership roles at WNS, IBM, Booz & Company, Symphony, IQVIA, KPMG Consulting, and PWC. Anbil has consulted with and counseled Health and Life Sciences clients on structuring solutions to address strategic, operational, and organizational challenges. He is a diplomat-in-residence at MIT CSAIL. He is a healthcare expert member of the World Economic Forum. He was a member of the IBM Industry Academy, a highly selective group of professionals inducted by invitation only and considered IBM's highest honor.
Satish Tadikonda is a Senior Lecturer in the Entrepreneurial Management Unit at Harvard Business School (HBS). In the MBA program, Satish has previously taught The Entrepreneurial Manager, a required first-year MBA course, and currently teaches two elective courses for second-year MBA students, Entrepreneurship in Life Sciences and Field Course: Life Sciences Venture Creation. Before joining the faculty, he served as an Executive Fellow in Entrepreneurship and Entrepreneur-in-Residence at HBS for six years, advising Harvard-based students and startups on all aspects of the entrepreneurial journey.
References
1. McKinsey & Company. Reimagining life science enterprises with agentic AI. Published September 8, 2025.
2. Deloitte Insights. AI in biopharma. Published 2022.
3. Huynh DL, Seal S, AIA4S Consortium, Reid D, Carpenter AE, Bender A, et al. AI agents in drug discovery: applications and case studies. Drug Discov Today. 2026;31(3):104650. doi:10.1016/j.drudis.2026.104650
4. Bentwich I. Pharma’s bio-AI revolution. Drug Discov Today. 2023;28(5):103515. doi:10.1016/j.drudis.2023.103515
5. Mihic A, Agrawal G, Yew H, Webster K, Van der Veken L, Jin L, et al. Agentic AI: unlocking peak performance in biopharma development. McKinsey & Company. Published December 11, 2025.
6. US Food and Drug Administration. Considerations for the use of artificial intelligence to support regulatory decision-making for drug and biological products: draft guidance for industry and other interested parties. Published January 2025.
7. International Council for Harmonisation. ICH E6(R3): guideline for good clinical practice. Published 2025.
8. International Council for Harmonisation. ICH E3: structure and content of clinical study reports. Published 1995.
9. ZS. Transforming pharma CRM with agentic AI and Salesforce. Published July 27, 2025.
10. Salesforce. How agentic AI in pharma is revolutionizing healthcare. Published 2025.
11. Medable. How agentic AI is transforming life sciences discovery and operations. Published December 16, 2025.
12. TraceLink. Building the foundation for agentic AI in life sciences and healthcare supply chains. Published December 3, 2025.
13. IQVIA. Exploring the value of agentic AI in life sciences. Published January 28, 2026.
14. Taylor K, Powell D, Ronte H. Intelligent post-launch patient support: enhancing patient safety with AI. Deloitte Insights. Published July 27, 2022.
15. Huang JY, Lee WP, Lee KD. Predicting adverse drug reactions from social media posts: data balance, feature selection and deep learning. Healthcare (Basel). 2022;10(4):618. doi:10.3390/healthcare10040618
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
HHS Confirms Four Senior FDA Leaders, Including Agency's First-Ever AI Deputy Commissioner
2
Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes
3
Artisan Partners’ Director Calls for Novartis Board Shake-Up
4
How Elevated Cortisol Levels Can Impact Type II Diabetes Treatments
5